TherapeuticsMD, Inc. (NASDAQ: TXMD) is engaged within the research, development and commercialization of healthcare products for women. Shares of the women’s’ health company are skyrocketing 362% through early trading on Tuesday, May 31, 2022. Over the past three months, TherapeuticsMD has seen average daily volume of 685,120 shares. However, volume of 4.61 million shares or dollar volume of around $45.55 million, has already exchanged hands through early trading.
Shares of TherapeuticsMD are soaring after the company announced that it has entered into a definitive agreement to be acquired by an affiliate of EW Healthcare Partners, a healthcare-focused private equity firm. Under the terms of the deal, EW Healthcare will acquire all outstanding shares of TherapeuticsMD common stock at a price per share of $10.00 in an all-cash transaction. The offer represents a massive 367.3% premium compared to TXMD’s closing price on May 27, 2022.
EW Healthcare Partners is among the largest and oldest private equity firms with a focus on healthcare investments. Since its inception, the firm has raised over $4 billion for its health ventures. During that time, EW Healthcare Partners has placed investments in over 150 companies across pharmaceuticals, medical devices, diagnostics, and more across the United States and Europe.
“We are pleased to welcome TherapeuticsMD to the EW Healthcare Partners portfolio and are deeply committed to the Company’s mission of advancing women’s health. EW Healthcare Partners has already made a significant investment in women’s health through its acquisition of Majorelle. TherapeuticsMD represents a unique opportunity for Majorelle to enter the US market and is a perfect fit with our ambitious plans to create a fast-growing, premier trans-Atlantic women’s health platform. We bring an extensive network and capital to fund the further growth of the combined company,” said Evis Hursever, Managing Director at EW Healthcare Partners.
Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/
